Evidence map›Paper›PMID 38367280›Full record

ArticleACS infectious diseases2024

High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of

Sandra Johannsen, Robin M Gierse, Arne Krüger, Rachel L Edwards, Vittoria Nanna, Anna Fontana, Di Zhu, Tiziana Masini, Lais Pessanha de Carvalho, Mael Poizat and 16 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 5 countries.

Sandra JohannsenHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.ORCID 0000-0003-2306-2071
Robin M GierseHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.
Arne KrügerUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo-SP 05508-000, Brazil.
Rachel L EdwardsDepartment of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri 63110, United States.
Vittoria NannaHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.ORCID 0000-0001-6430-7392
Anna FontanaHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.
Di ZhuHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.
Tiziana MasiniStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, Groningen 9747 AG, The Netherlands.
Lais Pessanha de CarvalhoInstitute of Tropical Medicine, University of Tübingen, Wilhelmstraße 27, Tübingen 72074, Germany.ORCID 0000-0002-3857-5462
Mael PoizatSymeres, Kadijk 3, Groningen 9747 AT, The Netherlands.
Bart KieftenbeltSymeres, Kadijk 3, Groningen 9747 AT, The Netherlands.
Dana M HodgeDepartment of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Sophie AlvarezProteomics & Metabolomics Facility, Center for Biotechnology, Department of Agronomy and Horticulture, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, United States.
Daan BuntStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, Groningen 9747 AG, The Netherlands.ORCID 0000-0002-2252-5751
Antoine LacourHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.
Atanaz ShamsHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.
Kamila Anna MeissnerUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo-SP 05508-000, Brazil.
Edmarcia Elisa de SouzaUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo-SP 05508-000, Brazil.
Melloney DrögeSymeres, Kadijk 3, Groningen 9747 AT, The Netherlands.
Bernard van VlietSymeres, Kadijk 3, Groningen 9747 AT, The Netherlands.
Jack den HartogSymeres, Kadijk 3, Groningen 9747 AT, The Netherlands.
Michael C HutterCenter for Bioinformatics, Saarland University, Campus Building E2.1, Saarbrücken 66123, Germany.ORCID 0000-0003-3168-6554
Jana HeldInstitute of Tropical Medicine, University of Tübingen, Wilhelmstraße 27, Tübingen 72074, Germany.
Audrey R Odom JohnDepartment of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.ORCID 0000-0001-8395-8537
Carsten WrengerUnit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 1374, São Paulo-SP 05508-000, Brazil.ORCID 0000-0001-5987-1749
Anna K H HirschHelmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, Saarbrücken 66123, Germany.ORCID 0000-0001-8734-4663
Flevoziekenhuis · NLHelmholtz Centre for Infection Research · DEUniversity of Groningen · NLUniversidade de São Paulo · BRChildren's Hospital of Philadelphia · USCentre de Recherche Médicales de Lambaréné · GASaarland University · DEUniversity of Nebraska–Lincoln · USUniversity of Tübingen · DEWashington University in St. Louis · US

Funding

MEP pathway resistance in Plasmodium falciparumR01AI103280 · NIAID · WASHINGTON UNIVERSITY · PI Audrey Ragan Odom John · 2013 to 2026
$5.5M
Structure-based microbially targeted prodrugsR01AI171514 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI DOWD, CYNTHIA SCHIECK, JEZ, JOSEPH MARTIN · 2022 to 2025
$4.0M
TARGETING ISPC TO TREAT MALARIAR21AI123808 · NIAID · WASHINGTON UNIVERSITY · PI ODOM JOHN, AUDREY RAGAN · 2016 to 2017
$440k
SELECTIVE INHIBITION OF THE P. FALCIPARUM GLUCOSE TRANSPORTER PFHTR21AI130584 · NIAID · WASHINGTON UNIVERSITY · PI HRUZ, PAUL W · 2018 to 2019
$419k
NIAID NIH HHS R01 AI103280NIAID NIH HHS R01 AI171514NIAID NIH HHS R21 AI123808NIAID NIH HHS R21 AI130584
6 · The paper itself

Abstract

In this study, we identified three novel compound classes with potent activity against

Indexed as

AntimalarialsMalaria, FalciparumThiazolesChloroquineHumansPlasmodium falciparum2-aminothiazoleAntimalarialsChloroquineThiazolesDXPSmalariaMEP pathwayPlasmodium falciparumPolypharmacology Browser

Identifiers

PMID38367280
PMCPMC10928712
OpenAlexW4391913643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.